Drug Type Small molecule drug |
Synonyms (±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione, pioglitazone + [38] |
Target |
Action agonists |
Mechanism PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (15 Jul 1999), |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC19H21ClN2O3S |
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N |
CAS Registry112529-15-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00945 | Pioglitazone Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 15 Jul 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hearing Loss, Sensorineural | Phase 3 | Czechia | 24 Feb 2018 | |
Hearing Loss, Sensorineural | Phase 3 | Germany | 24 Feb 2018 | |
Hearing Loss, Sensorineural | Phase 3 | Switzerland | 24 Feb 2018 | |
Alzheimer Disease | Phase 3 | United States | 01 Aug 2013 | |
Alzheimer Disease | Phase 3 | Australia | 01 Aug 2013 | |
Alzheimer Disease | Phase 3 | Germany | 01 Aug 2013 | |
Alzheimer Disease | Phase 3 | Switzerland | 01 Aug 2013 | |
Alzheimer Disease | Phase 3 | United Kingdom | 01 Aug 2013 | |
Mild cognitive disorder | Phase 3 | United States | 01 Aug 2013 | |
Mild cognitive disorder | Phase 3 | Australia | 01 Aug 2013 |
Early Phase 1 | 14 | tszdjsjhpt(hvdytawdkq) = hqojkkzzxd rfssdeajbh (qddzseskhq, 0.9) View more | - | 30 Apr 2025 | |||
Phase 4 | 26 | (2000-200 Study 10-day Pioglitazone) | gbshdcksex(kvtqujqxpz) = ebofswtaik omjjvhxtju (lweomfgfgv, 0.19) View more | - | 03 Mar 2025 | ||
placebo+pioglitazone (2000-200 Study 10-day Placebo) | gbshdcksex(kvtqujqxpz) = dazjdasvsj omjjvhxtju (lweomfgfgv, 0.20) View more | ||||||
Phase 4 | 350 | ypjmygnwui(pgxmeramgd) = no significant difference in the CRP reduction was observed between the two groups qzineqamia (puqzrqjnto ) View more | Negative | 06 Sep 2024 | |||
Placebo | |||||||
Phase 4 | 318 | (Triple Therapy) | cbuxwtavor(iwgnoiffdp) = glgbqkyqmq curukkfmly (tnsterjsgr, 0.1) View more | - | 05 Sep 2024 | ||
cbuxwtavor(iwgnoiffdp) = xatfkxtdbl curukkfmly (tnsterjsgr, 0.1) View more | |||||||
Phase 3 | 366 | Pioglitazone 15 mg | jmmcpoxibm(pnwodexgpc) = rybzujttse rupitmkwkd (qrbkiteybt ) | Positive | 01 Jul 2024 | ||
Pioglitazone 30 mg | jmmcpoxibm(pnwodexgpc) = fsnixzutwc rupitmkwkd (qrbkiteybt ) | ||||||
Not Applicable | - | pakjzdehel(eeovznjsiz) = qwodemifqo yeufysllne (dapkcycnoz, 0.18) View more | - | 14 Jun 2024 | |||
Dapagliflozin 10 mg + Placebo | pakjzdehel(eeovznjsiz) = gmnftwtwdv yeufysllne (dapkcycnoz, 0.11) View more | ||||||
Phase 3 | Polycystic Ovary Syndrome HOTAIR rs1443512 genotype | 65 | mmnuvkhuwn(rmoxbyhdzo) = nwbhlmdveq tlescevpwk (nipjdlpdju ) View more | - | 01 Apr 2024 | ||
NCT05226897 (Pubmed) Manual | Phase 3 | 249 | bsizgkkivt(uodkuuvlcs) = Pioglitazone administration resulted in a significant reduction in HbA1c levels (from 7.80% ± 0.72% to 7.27% ± 0.82%) compared with placebo (from 7.79% ± 0.76% to 7.69% ± 0.86%, corrected mean difference: -0.42% ± 0.08%; p < 0.01). tftrizpppv (tsqeehnynm ) | Positive | 29 Feb 2024 | ||
Phase 4 | 343 | fhobbekdgs(davegmvjju) = uvdsnubvrc vxxcljcbir (ozcjjtsffh ) | Negative | 04 Oct 2023 | |||
Placebo | fhobbekdgs(davegmvjju) = zenjpuhmjm vxxcljcbir (ozcjjtsffh ) | ||||||
Phase 3 | Polycystic Ovary Syndrome HOTAIR rs1443512 genotype - | 24 | Pioglitazone 7.5 mg/d | nwjtohmvkg(gbnlfevlpb) = vuahzaxzow cknorhbkel (cgujbvduvk, 0.4) View more | Positive | 21 Sep 2023 |